Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
Kaplan-Meier Estimates of Progression-free and Overall Survival,... | Download Scientific Diagram
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
Adding Olaparib to Bevacizumab Maintenance Improves Progression
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study - ScienceDirect
Avastin® (bevacizumab) Clinical Trials for Ovarian Cancer | HCP
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancer | MedPage Today
Avastin® (bevacizumab) Clinical Trials | MRCC Treatment
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study | Anticancer Research
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Bevacizumab in the Management of Epithelial Ovarian Cancer | touchONCOLOGY
Bevacizumab and chemotherapy for recurrent glioblastoma | Neurology
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis | PLOS ONE
Overall survival according to the addition of bevacizumab to first-line... | Download Scientific Diagram
Figure 3 from Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. | Semantic Scholar
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study | International Journal of Gynecologic Cancer
Improved Survival with Bevacizumab in Advanced Cervical Cancer | NEJM
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis | BMC Cancer | Full Text
Avastin® (bevacizumab) Clinical Trials | NSCLC Treatment
Landmark OS for HCC, updated IMbrave150 data - Medical Conferences
Bevacizumab Progression-free Survival Benefit Upheld in AVEREL Trial - The ASCO Post
When more is better: bevacizumab treatment for patients with ovarian cancer
